A Randomized, Double Blind, Third Party Open, Placebo Controlled Multi-Center Study Of Efficacy, Safety And Tolerability Of Pf-06743649 In Gout Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
Price : $35 *
At a glance
- Drugs PF 6743649 (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 08 Mar 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.